Gram-positive breakthrough infections pose a major drawback to the use of quinolones for antibacterial prophylaxis in neutropenic patients. Levofloxacin offers the advantage of an augmented Gram-positive spectrum and may potentially overcome this problem. In an openlabel, clinical pilot study, we investigated the effects on throat and bowel microflora and pharmacokinetics of a once-daily oral dose of 500 mg levofloxacin, during neutropenia in 20 patients with haematological malignancies. Gram-negative bowel flora and Staphylococcus aureus were successfully eradicated. No Gram-negative infections occurred. Minimal inhibitory concentration values for viridans group (VG) streptococci tended to increase, in four patients over 8 mg/l, indicating resistance to levofloxacin. Four patients developed blood-stream infections with levofloxacin-resistant Gram-positive cocci. No significant changes in numbers of anaerobic microorganisms were observed. Pharmacokinetic parameters of levofloxacin, including the maximum serum concentration (C max ), time to C max (T max ), area under the concentrationtime curve (AUC), volume of distribution at steady state (V ss /F) and clearance (CL/F) were not statistically different at first dose and during neutropenia. In conclusion, levofloxacin eradicates Gram-negative microorganisms and S. aureus and spares the anaerobic flora. Its pharmacokinetic profile is unaltered during neutropenia. However, prolonged administration of levofloxacin as antibacterial prophylaxis may be hampered by the emergence of levofloxacin-resistant VG streptococci. Quinolones are widely used for the prevention of bacterial infections during neutropenia in patients with haematooncological diseases. The quinolones are attractive for this purpose because they are active against a broad range of bacteria and are well tolerated. Moreover, quinolones have been shown to reduce the incidence of Gram-negative infections and fever in neutropenic patients significantly, although a reduction of mortality does not seem to occur.
positive infection; pharmacokinetics Quinolones are widely used for the prevention of bacterial infections during neutropenia in patients with haematooncological diseases. The quinolones are attractive for this purpose because they are active against a broad range of bacteria and are well tolerated. Moreover, quinolones have been shown to reduce the incidence of Gram-negative infections and fever in neutropenic patients significantly, although a reduction of mortality does not seem to occur. 1 Of concern is the increased incidence of Gram-positive infections, which has been noted even in the first reports on the use of quinolones for the prevention of Gram-negative bacteraemia. 2, 3 Especially, viridans group (VG) streptococci and coagulase-negative staphylococci have emerged as important pathogens in patients receiving quinolone prophylaxis. 2, 4, 5 To solve this problem, it has been attempted to augment the Gram-positive activity of the prophylactic regimen by the addition of a second antimicrobial agent, such as roxitromycin, rifampicin or penicillin. This approach indeed has been reported to result in significantly lower rates of gram-positive infections. [5] [6] [7] [8] [9] [10] Recently, quinolone agents with enhanced Gram-positive activity have become available. A new fluoroquinolone, levofloxacin, shows excellent in vitro activity against many Gram-positive bacteria, including streptococci, enterococci and staphylococci, yet the drug retains the potent Gramnegative activity of earlier quinolones. 11, 12 The pharmacokinetic profile of the drug is compatible with a once-daily dosing regimen. Considering these properties, levofloxacin seems an appealing agent for antimicrobial prophylaxis in neutropenic patients, and the drug has been readily applied as such by some centres. However, the consequences of this approach, from a microbiological point of view, remain largely unresolved. Issues like the development of antimicrobial resistance during prolonged administration of levofloxacin and its effect on microbiological flora have not been subject to prospective or systematic evaluation. Moreover, pharmacokinetics of levofloxacin have been studied in healthy volunteers only 13, 14 and pharmacokinetic parameters such as absorption and bioavailability may be significantly altered in neutropenic patients, due to the underlying disease, chemotherapeutic regimen and the occurrence of mucosal damage. 15, 16 We therefore conducted this open-label, nonrandomized clinical pilot study to evaluate the pharmacokinetic profile of oral levofloxacin and to study its effect on throat and bowel microflora in neutropenic patients with haematological malignancies.
Patients and methods

Patients
Patients aged 18-75 years, hospitalized at the Haematology Department of the VU University Medical Centre and scheduled to receive high-dose combination chemotherapy, with or without autologous haematopoietic stem-cell rescue, were eligible for this study. An anticipated granulocytopenic period (granulocytes o0.5 Â 10 9 /l) of at least 10 days was required. Patients were excluded if they had a history of allergy to quinolones or if they had infection requiring treatment at entry. Treatment with any antimicrobial or antifungal drug within 2 weeks prior to enrolment was also a reason for exclusion, as was the use of aluminium or magnesium containing antacid drugs. Patients with hepatic or renal impairment, respectively, defined as elevation of any liver function test greater than three times the upper limit of normal or an estimated creatinine clearance of less than 15 ml/min, were not included. The aim of this study was to enroll 20 subjects. Patients who had to discontinue the study or were withdrawn for reasons not related to the study drug were to be replaced. The protocol was approved by the institutional scientific and ethical committees and all participating patients provided written informed consent.
Study drug and anti-infective measures
All patients received one 500 mg tablet of levofloxacin, once daily at 10.00 a.m. Treatment was started on the first day of chemotherapy and continued until recovery of neutrophils, defined as an absolute neutrophil count (ANC) 40.5 Â 10 9 /l. In addition, for prevention purposes patients received fluconazole 50 mg once daily and nasal amphotericin B 2 mg three times a day. Daily clinical assessments were performed, including documentation of signs and symptoms of infection and registration of compliance and tolerance to the study medication. If clinical signs and symptoms of infection occurred, or if axillary temperature increased above 38.51C, patients were evaluated and started on empirical antibiotic treatment with imipenem 500 mg four times daily i.v. Prophylaxis with levofloxacin was to be continued. If no defervescence occurred within 4 Â 24 h, amphotericin B 0.7 mg/kg i.v. was added to the antimicrobial regimen.
Microbiological methods
Throat swabs and faecal samples were collected before the first dose and afterwards twice weekly, on Tuesday and Friday. If the patient was unable to produce a faecal sample, a rectal-swab specimen was taken. Throat and rectal culture samples were obtained with soluble calciumalginate swabs, stored in 10 ml transport medium. Subsequently, 0.1 ml of 10-fold dilutions of faecal samples or swab specimens were cultured on sheep blood agar (Oxoid Ltd, Basingstoke, UK) Mannitol salt agar (Oxoid) and MacConkey 1 agar (Oxoid) for 2 days at 371C, Sabouraud dextrose agar (BBL, Becton-Dickinson and Co., Cockeysville, MD, USA) for 7 days at 371C and Sabouraud dextrose agar (Becton-Dickinson) for 7 days at 301C. For quantitative anaerobic culture 10-fold dilutions of faecal and throat-swab specimens were cultured on 5% horse blood agar (Oxoid) supplemented with haemin/menadione for 7 days at 371C under anaerobic conditions. The identification of microorganisms at the species level was performed by standard microbiological techniques. For the determination of anaerobic bacteria, subcultures were made (50-100 colonies) for aerobic and anaerobic incubation and Gram staining was performed. The results for Staphylococcus aureus, aerobic Gram-negative bacilli, yeasts, anaerobic Gram-negative and gram-positive bacilli were reported as the number of colony-forming units per gram faeces (CFU/g) or per millilitre for throat-swab specimens (CFU/ml). For throat swabs, the number of VG streptococci was determined (CFU/ml). The antimicrobial activity of levofloxacin on S. aureus, VG streptococci and Gram-negative bacilli was tested by the determination of the minimal inhibitory concentration (MIC) by E-test (AB Biodisk, Solna, Sweden). Breakpoints for levofloxacin were defined according to NCCLS standards, as susceptible (MICp2 mg/ml), intermediate resistant (MIC ¼ 4 mg/l) and resistant (MICX8.0 mg/l).
Pharmacokinetic methods
The assessment of pharmacokinetic parameters of levofloxacin was performed in 10 subjects (50%), being the first cohort of 10 patients enrolled in the study. The pharmacokinetic study consisted of two phases. During phase 1, samples (7 ml) of venous blood were collected from an indwelling central venous catheter, immediately prior to the administration of the first dose of levofloxacin, and at 0.5, 1.0, 2.0, 4.0, 6.0, 8.0, 12.0, 18.0 and 24.0 h after administration. Phase 2 was initiated as soon as the patient was profoundly granulocytopenic (ANCo0.5 Â 10 9 /l). Venous samples were drawn, immediately prior to dosing and at 1.0, 4.0, 8.0, 18.0 and 24.0 h after dosing. All samples were collected in standard tubes and centrifuged after clotting. The serum was separated and stored at À201C until analysis. To investigate whether levofloxacin undergoes in vivo enantioconversion from S-(À)-ofloxacin (levofloxacin) to R-( þ )-ofloxacin, urine samples were collected from each patient within 10 h after the administration of the first oral dose of levofloxacin. Urine samples were stored at À201C.
Venous blood samples were assayed by reversed phase high-pressure liquid chromatography with diode array detection (Gynkotek, Germering, Germany). Separations were carried out on a 3.9 Â 150 mm 2 Symmetry C 18 column (Waters, Milford, MA, USA), using ciprofloxacin as an internal standard. The mobile phase was 25 mM phosphate buffer (pH 3.0): acetonitrile (85:15). Chromatography was performed at ambient temperature and a flow rate of 1.0 ml/min. Detection wavelength was at 290 nm. The analysis of the urine samples was carried out on a Beckman P/ACE 5500 capillary electrophoresis system (Beckman Instruments, Fullerton, CA, USA) equipped with a diode array detector, using 0.35 mM sulphated b-cyclodextrin as a chiral selector. Detection wavelength was at 291 nm.
From the data obtained, the apparent total body clearance (CL/F), apparent volume of distribution at steady state (V ss /F), maximum concentration in the serum (C max ), time to maximum concentration in the serum (T max ) and area under the curve for the 24-h dosing interval (AUC 0-24 ) of levofloxacin were determined. Patients were tested for differences between phase 1 and 2 pharmacokinetics, with each patient being its own control. Pharmacokinetic calculations were performed with the MW/Pharm software (MediWare, Groningen, The Netherlands), which is capable of curve fitting and simulations according to a one-, two-or three-compartment model, and provides compartmental and noncompartmental pharmacokinetic parameters. An extravascular, two-compartment model with lag time was found to best describe the data.
Statistical analysis
Changes in the number of CFUs of anaerobes in faecal samples and swab specimens over time were analysed by regression analysis. The regression coefficient (B) and its 95% confidence interval (CI) were calculated. Subsequent analysis of variance was performed to assess goodness-of-fit of the line. A paired Student's t-test was used for the statistical analysis of differences in mean pharmacokinetic parameters between phases 1 and 2. All tests were twosided and a P-value less than 0.05 was considered statistically significant.
Results
Patient characteristics
In all, 22 patients were enrolled in the study, two of which were excluded from analysis. One patient was not evaluable because he erroneously received concomitant antibacterial prophylaxis with trimethoprim-sulphamethoxazole, the other patient died a week after entry from cerebral haemorrhage due to thrombocytopenia. Characteristics of the remaining 20 evaluable patients are given in Table 1 . All patients tolerated the study drug well, no adverse effects occurred, which could be attributed to levofloxacin. The mean number of levofloxacin doses received per patient was 22, no missed doses were reported.
Microbiological results
During the course of the study, a total of 137 throat swabs (mean 6.9/patient) and 115 faecal samples (mean 5.8/ patient) were collected. In all, 17 anal swabs had to be taken because the patient was not able to produce a stool specimen. Culture data of the throat-swab specimens are summarized in Table 2 . VG streptococci persisted from the start of chemotherapy throughout the duration of the neutropenic episode. At day 0-1, VG streptococci were highly susceptible to levofloxacin in 19 patients (MIC p1 mg/l), in one patient an intermediate-susceptible strain was found (day 2, MIC ¼ 4 mg/l). During the prophylactic administration of levofloxacin in four patients, VG streptococci were isolated with MIC values increasing in one step up to X32 mg/l, this occurred, respectively, after 11, 13, 14 and 21 days of treatment. These patients received additional prophylaxis with oral penicillin, 250 mg four times daily.
MIC values of VG streptococci that remained susceptible to levofloxacin (MICp2 mg/l) were analysed separately, leaving resistant strains out of the calculations. Even in these susceptible strains there was a gradual but significant increase of MIC values during the study period (regression coefficient B ¼ 0.03, CI 95 0.01-0.04, P ¼ 0.03).
Culture data of faecal samples are given in Table 3 . On admission 18/20 (90%) of patients were colonized with Enterobacteriaceae or other Gram-negative microorganisms (CFU410 3 /g faeces), in two patients S. aureus was identified (CFU410 3 /g faeces). Successful eradication of these microorganisms was achieved within 5 days of levofloxacin administration. Two patients were colonized with a levofloxacin resistant Escherichia coli on admission (MICX32 and 12 mg/l, respectively). In a third patient, a levofloxacin-resistant Escherichia coli (MICX32 mg/l) was isolated from a stool specimen during the second week of his admission (day 13). In addition to levofloxacin, these three patients received oral colistin, 300 mg three times daily, which provided adequate eradication of levofloxacin- resistant E. coli. In one patient an Acinetobacter lwoffii was isolated on day 6 and in another patient a Sphingomonas paucimobilis was found on day 12. Both strains were considered transient flora because they proved to be susceptible to levofloxacin and were isolated only once. Quantitative anaerobic cultures of throat-swab specimens obtained at baseline showed a mean number of 6.2 Â 10 6 CFU/ml (range 3.0 Â 10 6 -7.4 Â 10 6 CFU/ml). A predominance of anaerobic Gram-positive bacilli was found in throat samples, subdivided into cocci (21%) and rods (49%). In faecal samples obtained at baseline, a mean number of anaerobic bacilli of 1.6 Â 10 9 CFU/g (range 1.4 Â 10 5 -1.3 Â 10 10 CFU/g) was found, which were mainly Gram-negative rods (90%). No significant changes of colonization rates of anaerobes over time were observed, as expressed by the total number of CFU/g faeces Table 2 Culture data of throat-swab specimens Fever, defined as a sustained axillary temperature of 438.51C, occurred in eight (40%) patients. Probable causes of fever were a clinically documented infection of the lung (n ¼ 2), an infection of the skin with Absidia spp (n ¼ 1) and fever of unknown origin (n ¼ 1). Four patients developed blood-stream infections with Gram-positive bacteria, including coagulase-negative staphylococcus (n ¼ 1), Enterococcus faecalis (n ¼ 1), S. oralis (n ¼ 1) and E. faecium þ coagulase-negative staphylococcus (n ¼ 1). All isolated microorganisms displayed high level resistance to levofloxacin (MICX32). Patients with fever received imipenem as initial empirical antibiotic treatment. In two patients vancomycin was added, because of imipenemresistant pathogens (E. faecium, coagulase-negative staphylococcus). In another two patients imipenem was switched to vancomycin in combination with aztreonam, because of an allergic skin reaction possibly due to imipenem. Amphotericin B was given to two patients, one with a proven infection with Absidia spp and another because of persisting fever after 4 Â 24 h of treatment with imipenem. All patients with fever recovered without significant sequelae. There was no mortality attributable to infectious complications.
Pharmacokinetic data
Urine samples were collected in 10 patients. No in vivo enantioconversion from S-(À)-ofloxacin (levofloxacin) to R-( þ )-ofloxacin was observed. For this reason, it was not necessary to use an enantio-selective separation method for the analysis of the blood samples.
A total of 170 venous blood samples were drawn in 10 patients. In all, 10 samples per patient were collected during the 24 h period following first dose administration (phase 1), seven samples per patient were obtained immediately after neutropenia had been established (phase 2). Phase 2 sampling was initiated at a mean of 13.973.8 days from first dose administration. At that time all patients were neutropenic (ANC o0.5 Â 10 9 /l), 8/10 (80%) of patients had a total leucocyte count of p0.1 Â 10 9 /l. The mean concentrations found in the serum following the first dose of 500 mg levofloxacin (phase 1) and at neutropenia (phase 2) are shown in Figure 1 . The derived mean7s.d. pharmacokinetic parameters are listed in Table 4 . There was no statistically significant difference between the mean area under the concentration-time curve at first dose (AUC 0-10 ) and during neutropenia (AUC 0-24 multiple doses at steady state) (P40.05). Also no statistically significant differences were found in mean values of the maximum concentration of levofloxacin in the serum (C max ), the time to maximum concentration in the serum (T max ), the apparent volume of distribution at steady state (V ss /F) and the apparent total body clearance (CL/F) (P40.05). These data indicated that the systemic availability of levofloxacin and its serum concentration-time profile were equivalent for administration at day 1 and during neutropenia.
Discussion
Levofloxacin is a new fluoroquinolone, with increased activity against Gram-positive bacteria, yet it retains good activity against Enterobacteriaceae and other Gram-negative microorganisms. The present study was conducted to resolve two major issues with regard to the use of levofloxacin as antibacterial prophylaxis in neutropenic subjects. First, to assess the effect of multiple dose administration of levofloxacin on gastrointestinal microflora and second, to investigate its pharmacokinetic profile during neutropenia. Table 4 Pharmacokinetic parameters of levofloxacin in the first cohort of 10 study patients, at baseline and during neutropenia (neutrophil count o0.5 Â 10 9 /l) Phase C max (mg/ml) T max (h) AUC 0À24 (h mg/ml) V ss /F (l) V ss /F (l/kg) CL/F (ml/min) CL/F (ml/min/kg) Cmax, maximum concentration in serum; Tmax, time to maximum concentration in serum; AUC0-24, area under the curve for the 24-h dosing interval; Vss/F, apparent volume of distribution at steady state; CL/F, apparent total body clearance.
As expected, levofloxacin provided excellent eradication of Enterobacteriaceae within 5 days from the start of antibacterial prophylaxis. In line with the preclinical data, the median MIC values of levofloxacin for E. coli, Klebsiella spp and Enterobacter spp were very low, except for two patients who were already colonized with a levofloxacin-resistant E. coli on admission (MICX32 and 12 mg/l, respectively). In addition, one patient appeared to be colonized with a resistant E. coli during the second week of his admission. Resistance of E. coli to levofloxacin is uncommon. However, the systematic use of ciprofloxacin prophylaxis in neutropenic subjects has been clearly associated with the emergence of quinolone-resistant E. coli. [17] [18] [19] [20] Our observation indicates that levofloxacin may be expected to induce resistance in Gram-negative microorganisms to a comparable extent as ciprofloxacin. We used additional prophylaxis with oral colistin in these patients. This resulted in the eradication of the levofloxacin-resistant strains. In a recent publication, the addition of colistin to ciprofloxacin appeared to reduce the emergence of quinolone-resistant Gram-negative bacteria and to prevent Gram-negative sepsis in neutropenic patients. 18 In our patients no systemic infections with Gram-negative bacteria occurred.
Colonization with VG streptococci was reduced by the prophylactic administration of levofloxacin. Of concern was the increase of MIC values for streptococci over time. In four patients VG streptococci with MICs of X32 mg/l were isolated during the course of antibacterial prophylaxis. In addition, even for VG streptococci that remained susceptible to levofloxacin, a significant gradual increase of MIC values was found during the study period. In vitro studies have demonstrated high susceptibility of VG streptococci to levofloxacin, with MIC values ranging from 0.25 to 1 mg/l. 21, 22 Our data indicate that resistance of VG streptococci may develop during long-term administration of levofloxacin. This observation is in line with recently published clinical data. 23 In a series of 37 neutropenic patients receiving levofloxacin prophylaxis, bacteraemia with VG streptococci occurred in six (16%) patients, three of whom developed septic shock. All isolates displayed diminished susceptibility to levofloxacin and crossresistance to other quinolones. The authors conclude that the prophylactic administration of levofloxacin may result in the selection of quinolone-resistant VG streptococci.
Four patients in our study developed blood-stream infections with Gram-positive bacteria, including coagulase-negative staphylococci, E. faecalis, S. oralis and E. faecium. Preclinical data show that most strains of enterococci and coagulase-negative staphylococci are susceptible to levofloxacin, although MIC values are higher than for VG streptococci. MIC values are reported to range from 0.13 to 4 mg/l for coagulase-negative staphylococci and from 0.25 to 32 mg/l for enterococci. 21, 22 In a study on haemato-oncology patients in Switzerland, 65% of strains of coagulase-negative staphylococci were susceptible to levofloxacin and even 100% of strains of enterococci. 24 Despite these compelling data, our findings indicate that during levofloxacin prophylaxis breakthrough infections with coagulase-negative staphylococci or enterococci may occur.
Levofloxacin did not affect the anaerobic component of the gut microflora. The number of anaerobic microorganisms, expressed as the number of CFU/g faeces or per ml throat-swab specimen, did not change significantly during the course of the prophylactic regimen. This may be of crucial importance in view of preservation of colonization resistance, which is based on the concept that selective suppression of the aerobic Gram-negative bacteria in the digestive tract, without the impairment of the anaerobic flora, prevents the adherence, proliferation and invasion of potentially pathogenic bacterial and fungal species. 25 Our study is the first to report pharmacokinetic data of levofloxacin in neutropenic patients. The estimated mean values for C max , T max , AUC and CL/F in patients with haematological malignancies were well comparable with those determined in healthy subjects. 13, 26 In addition, we showed that individual pharmacokinetic parameters calculated after the first oral administration of levofloxacin were not statistically different from those calculated at neutropenia. This is important because significant changes in the pharmacokinetic profile may occur in patients receiving intensive chemotherapy. Mucosal damage, for example, may either decrease or increase the rate of antibiotic absorption, shifts and decreases in the serum albumin may significantly affect the volume of distribution of the drug. It has been shown previously that the absorption of oral ciprofloxacin and to a lesser extent of oral ofloxacin are reduced following cytotoxic chemotherapy. 15, 16 Pharmacokinetics of levofloxacin appear to be unaffected by the administration of chemotherapy or neutropenia, indicating that on these occasions there is no need for dose adjustment.
In conclusion, levofloxacin, administered orally as antibacterial prophylaxis to patients receiving intensive chemotherapy for haematological malignancies, provides adequate eradication of Gram-negative microorganisms and S. aureus and preserves the anaerobic component of the bowel flora. Moreover, the pharmacokinetic properties of levofloxacin are not altered due to chemotherapy or neutropenia. Levofloxacin is easily administered once daily and well tolerated. Of concern, however, is the increasing resistance of VG streptococci during prolonged administration of levofloxacin and a diminished susceptibility of coagulase-negative staphylococci and enterococci. These findings may hamper its use as a single agent for prophylaxis in neutropenic subjects. This pilot study, however, with a limited number of subjects does not allow for definite conclusions on that issue. Hence, the question remains open as to how levofloxacin prophylaxis compares with standard prophylactic regimens as for tolerability, efficacy, induction of resistance and the number of breakthrough infections. To address these questions, we are currently investigating levofloxacin vs ciprofloxacin plus oral penicillin in a randomized clinical trial.
